9 completed, 1 active not recruiting, 1 terminated, 1 withdrawn. 12 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 9, Active not recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 3 | 2 | Terminated 1, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow ABX464: new trials by email Literature Review of ABX464 trials Research Report on ABX464
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease Patients ABX464, Placebo - Crohn Disease | Phase 2 / Phase 3 | Withdrawn | Abivax S.A. | 2022-09-19 | 2024-07-31 | |
| Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis ABX464 - Ulcerative Colitis | Phase 2 | Active not recruiting | Abivax S.A. | 203 | 2021-12-03 | 2026-04-27 |
| ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19 ABX464, Placebo - COVID-19 | Phase 2 / Phase 3 | Terminated | Abivax S.A. | 509 | 2020-07-01 | 2025-11-26 |
| Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis ABX464 - Ulcerative Colitis | Phase 2 | Completed | Abivax S.A. | 217 | 2020-01-13 | 2026-05-06 |
| Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis ABX464 - Rheumatoid Arthritis | Phase 2 | Completed | Abivax S.A. | 40 | 2019-10-25 | 2025-11-17 |
| Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis ABX464 100 mg, ABX464 50 mg, ABX464 25 mg - Ulcerative Colitis | Phase 2 | Completed | Abivax S.A. | 355 | 2019-08-13 | 2025-11-28 |
| Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid Arthritis ABX464 50mg, Matching Placebo, ABX464 100mg - Rheumatoid Arthritis | Phase 2 | Completed | Abivax S.A. | 60 | 2019-07-04 | 2023-02-15 |
| Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis ABX464 - Ulcerative Colitis | Phase 2 | Completed | Abivax S.A. | 22 | 2018-01-20 | 2025-05-29 |
| ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis ABX464, Placebo oral capsule - Ulcerative Colitis | Phase 2 | Completed | Abivax S.A. | 32 | 2017-11-16 | 2024-06-03 |
| A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults ABX464 150mg, ABX464 50mg - HIV Infections, Health Volunteers | Phase 1 / Phase 2 | Completed | Abivax S.A. | 36 | 2017-03-27 | 2023-03-31 |
| ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment ABX464, Placebo - HIV Infection | Phase 2 | Completed | Abivax S.A. | 30 | 2016-05-01 | 2024-09-19 |
| Safety, PK and PD Study of ABX464 in Untreated HIV Patients ABX464, Placebo - Human Immunodeficiency Virus Infections | Phase 2 | Completed | Abivax S.A. | 70 | 2015-01-01 | 2016-05-30 |
Colitis, Ulcerative (5) · Arthritis, Rheumatoid (2) · HIV Infections (2) · COVID-19 (1) · Crohn Disease (1)
Abivax S.A. (12)
Belgium (10) · France (8) · Spain (7) · Hungary (6) · Poland (6) · Czechia (5) · Germany (5) · Austria (4) · Italy (4) · Canada (3) · Serbia (3) · Slovakia (3) · Slovenia (3) · Ukraine (3) · United Kingdom (3)
Bram Verstockt, MD (1) · Laurence Desroys du Roure, PharmD (1)
PMID 28507108, PMID 30800421, PMID 34436569, PMID 35641124, PMID 36075249, PMID 40417999